RESEARCH TRIANGLE PARK, N.C. - May 1, 2001 - Quintiles Transnational Corp. (Nasdaq: QTRN) today announced the opening of its state-of-the-art stability storage facility at its pharmaceutical development site in Kansas City, Mo.
The new 3,200-square-foot facility features some of the largest chambers and most comprehensive technology available in the contract pharmaceutical industry for the storage of pharmaceutical samples in development. These storage facilities complement and allow for further expansion of the Kansas City facility's formulation development and analytical testing capabilities. Stability storage and testing assists in determining the shelf life of drugs under various conditions of temperature and humidity.
"The opening of this new facility enhances Quintiles' ability to offer the best quality service to our customers," said Mike Baltezor, Chief Operating Officer, Quintiles Pharmaceutical Sciences. "No other contract pharmaceutical laboratory can offer the diversity of climate conditions that we are now able to provide. The size and variety of our walk-in stability chambers combined with our facilities in Edinburgh, Scotland, allow us to meet customer demands for storage and testing of samples for the most far-reaching clinical studies and commercial products."
The facility's new reach-in and walk-in chambers are designed to store a broad spectrum of traditional, biotechnology, controlled substance and medical device samples. The facility offers a wide variety of storage, temperature and humidity conditions, as recommended by the International Conference on Harmonization stability guidelines. In addition, all chambers are monitored by a Kaye LabWatch monitoring system--one of the largest installed by Kaye Instruments to date--which provides a continuous record of environmental conditions and instantaneous feedback on each stability chamber 24 hours a day.
"We are delighted to offer our customers a stability chamber facility that can meet their storage needs," said Baltezor. "Thanks to these significant new enhancements, we can now increase our offerings in stability storage and analytical testing and enhance our long-established early development services. We believe that the advanced technological capabilities of this new facility, combined with the extensive expertise of our employees in both Kansas City and Edinburgh, will make Quintiles a premier provider of stability storage and analytical testing."
Quintiles Pharmaceutical Sciences provides drug development and customized support services to pharmaceutical, biotechnology and medical device companies worldwide from facilities in Edinburgh, Scotland and Kansas City, Mo. Pharmaceutical Sciences services include: analysis, formulation, stability, dissolution testing, preformulation/physical chemistry testing, clinical trial and commercial manufacturing.
Quintiles Transnational Corp. is the world's leading provider of information, technology and services to bring new medicines to patients faster and improve health care. Headquartered near Research Triangle Park, North Carolina, Quintiles employs a global workforce of 18,000 in 39 countries. Quintiles Transnational is a member of the S&P 500 and Fortune 1000. For more information, visit the company's Web site at www.quintiles.com.
Information in this press release contains "forward-looking statements." These statements involve risks and uncertainties that could cause actual results to differ materially, including without limitation, actual operating performance of the new facility and risks associated with new equipment and technology. Additional factors that could cause actual results to differ materially are discussed in the company's recent filings with the Securities and Exchange Commission, including but not limited to its Annual Report on Form 10-K, its Form 8-Ks, and its other periodic reports, including Form 10-Qs.